Drug intelligence / Profile preview

lactobacillus reuteri GMNL-263 + lactobacillus reuteri GMNL-89 + lactobacillus rhamnosus GMNL-74

Development stage: Unknown
Lead developer: GenMont Biotech
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This is a combination product consisting of the probiotic strains **Lactobacillus reuteri GMNL-263**, **Lactobacillus reuteri GMNL-89**, and **Lactobacillus rhamnosus GMNL-74**. These strains are used together as a **multi-strain probiotic supplement**, predominantly formulated for oral administration (sometimes including both heat-killed and live bacterial forms). This probiotic combination is being studied for its beneficial effects on metabolic liver diseases such as **nonalcoholic fatty liver disease (NAFLD)**, and has also been investigated in animal models for its potential to **ameliorate hepatic inflammation and apoptosis in autoimmune conditions such as systemic lupus erythematosus (SLE)**[1][3][4]. The mechanism of action is implied to involve modulation of the gut microbiota, strengthening of intestinal barrier function, and reduction of inflammatory signaling through inhibition of the MAPK and NF-κB pathways, resulting in decreased liver cell apoptosis and inflammatory mediator expression[1][3].

Beyond the preview

Go deeper on lactobacillus reuteri GMNL-263 + lactobacillus reuteri GMNL-89 + lactobacillus rhamnosus GMNL-74.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus reuteri GMNL-263 + lactobacillus reuteri GMNL-89 + lactobacillus rhamnosus GMNL-74.

Explore the full profile